This study tests a drug called IMP4297 (a PARP inhibitor) as a long-term maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this pill daily can delay the cancer from ret…
Phase: PHASE3 • Sponsor: Impact Therapeutics, Inc. • Aim: Disease control
Last updated May 17, 2026 06:20 UTC